Advertisement

Topics

Aimmune's peanut drug moves closer to European market

07:00 EDT 26 Mar 2019 | BioPharmaDive

AR101 hit the primary endpoint of a Phase 3 European study, results Aimmune intends to include in a mid-year submission to the EMA.

Original Article: Aimmune's peanut drug moves closer to European market

NEXT ARTICLE

More From BioPortfolio on "Aimmune's peanut drug moves closer to European market"

Advertisement
Quick Search
Advertisement
Advertisement